deltatrials
Completed PHASE2 INTERVENTIONAL 8-arm NCT02569710

A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of the Combination of AL-335, Odalasvir, and Simeprevir

A Phase 2a, Open-Label Study to Evaluate the Safety, Pharmacokinetics and Efficacy of the Combination of AL-335 and Odalasvir, With or Without Simeprevir, in Treatment-Naïve Subjects With Genotype 1, 2 or 3 Chronic Hepatitis C Infection With or Without Compensated Child Pugh A Cirrhosis

Sponsor: Alios Biopharma Inc.

Conditions Chronic Hepatitis C
Interventions AL-335 Odalasvir (ODV) Simeprevir (SMV)
Updated 14 times since 2017 Last updated: Jun 24, 2019 Started: Oct 31, 2015 Primary completion: May 11, 2018 Completion: May 11, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Chronic Hepatitis C and is currently completed. Alios Biopharma Inc. leads this study, which shows 14 recorded versions since 2015 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jul 2017 · 5 months · monthly snapshot~Jul 2017 – ~Oct 2017 · 3 months · monthly snapshot~Oct 2017 – ~Jun 2018 · 8 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Aug 2019 · 12 months · monthly snapshot~Aug 2019 – ~Jan 2021 · 17 months · monthly snapshot~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshot~Dec 2021 – ~Jan 2022 · 31 days · monthly snapshot~Jan 2022 – ~Mar 2022 · 59 days · monthly snapshot~Mar 2022 – ~Jul 2024 · 28 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 9 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Mar 2022 — Jul 2024 [monthly]

    Completed PHASE2

  5. Jan 2022 — Mar 2022 [monthly]

    Completed PHASE2

▶ Show 9 earlier versions

  1. Dec 2021 — Jan 2022 [monthly]

    Completed PHASE2

  2. Jan 2021 — Dec 2021 [monthly]

    Completed PHASE2

  3. Aug 2019 — Jan 2021 [monthly]

    Completed PHASE2

  4. Aug 2018 — Aug 2019 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  5. Jun 2018 — Aug 2018 [monthly]

    Active Not Recruiting PHASE2

  6. Oct 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  7. Jul 2017 — Oct 2017 [monthly]

    Recruiting PHASE2

  8. Feb 2017 — Jul 2017 [monthly]

    Recruiting PHASE2

  9. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

Oct 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Alios Biopharma Inc.
Data source: Alios Biopharma Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations